GET DAILY SIGNALSInfuSystem Holdings (INFU) Delays Q3 2026 Earnings Release Over Accounting Review
Key Takeaways
- InfuSystem Holdings postponed its third quarter 2026 earnings release, which had been scheduled for November 3, 2026, citing the need for additional time to complete its quarter-end financial reporting.
- The delay centers on an accounting evaluation of approximately $4.2 million in ERP (enterprise resource planning) implementation costs, which the company has expensed as incurred since July 2024.
- Consensus estimates call for third quarter earnings per share (EPS) of about $0.13 and revenue near $37.28 million, compared with EPS of $0.11 and revenue of $36.49 million a year earlier.
- In its most recent quarter, the company beat expectations with EPS of $0.15 and revenue of $36.9 million, supported by strong Patient Services growth despite ongoing GE HealthCare contract headwinds.
- For deeper coverage, explore the ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- You can also explore Trending AI Robots to discover AI-driven trading strategies across the market.
The Context Behind the Earnings Delay
InfuSystem Holdings operates a two-platform model focused on Patient Services and Device Solutions in the healthcare space. The company has relied on higher-margin areas such as oncology and wound therapy within Patient Services to counterbalance softness in Device Solutions stemming from a restructured GE HealthCare contract. This shift has helped improve gross margins and adjusted EBITDA even as revenue growth stays modest. The sudden postponement of the third-quarter report introduces uncertainty around the reporting process itself, which makes the upcoming release especially relevant for investors looking for clarity on both operating results and the accounting treatment of those ERP costs.
What Analysts Are Expecting
For the third quarter ended September 30, 2026, consensus estimates point to EPS of roughly $0.13, an increase from the $0.11 posted in the same period last year. Revenue is projected near $37.28 million, which would represent about 2.2% year-over-year growth from $36.49 million, with the range spanning approximately $37.0 million to $37.55 million. These figures come after a solid second quarter in which INFU reported EPS of $0.15 versus a $0.11 consensus and revenue of $36.9 million against a $36.35 million forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors will be focused on whether Patient Services momentum holds and if Device Solutions shows signs of stabilization. The company has kept its full-year 2026 guidance intact, calling for 6% to 8% pro forma revenue growth and adjusted EBITDA margins in the low-to-mid 20% range.
Market Reaction and Recent Performance
Sentiment ahead of the report has been affected by the last-minute delay. Shares declined about 7.5% on November 3, 2026, following the disclosure that more time was needed for financial reporting and that the company was reviewing whether certain ERP implementation costs should be capitalized instead of expensed. The company noted that any change would be non-cash and would not impact revenue or cash balances, yet the timing and the accounting review have added a new layer of uncertainty. Historically, INFU shares have shown sharp moves around earnings, which is typical for this small-cap name.
Key Factors to Monitor Going Forward
The revised earnings date and the outcome of the ERP cost evaluation are the immediate items to track. A decision to capitalize the roughly $4.2 million in implementation costs could shift expense recognition across future periods, although the company has stressed that any adjustment would remain non-cash. Beyond that, attention should stay on the sustainability of Patient Services growth in oncology and wound therapy, which have driven recent margin gains. The company aims for adjusted EBITDA margins approaching 25% over the next two to three years, so the margin path will serve as an important indicator of progress. The Device Solutions segment, which has faced revenue pressure from the GE HealthCare contract changes, also warrants watching for any signs of stabilization. Full-year guidance for 6% to 8% pro forma revenue growth remains the key benchmark for the quarter.
Exploring Market Opportunities with Tickeron Tools
I frequently use Tickeron’s AI Screener when evaluating stocks in sectors like healthcare services. It allows me to apply filters for technical patterns, fundamentals, and performance metrics, helping surface comparable names and potential signals more efficiently than manual review. This has been particularly useful for placing INFU in context with peers and identifying broader trends in the space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INFU saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for INFU moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 57 similar instances where the indicator exited the overbought zone. In 46 of the 57 cases the stock moved lower. This puts the odds of a downward move at 81%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for INFU moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 15 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Moving Average Convergence Divergence Histogram (MACD) for INFU turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 65 similar instances when the indicator turned negative. In 51 of the 65 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INFU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
INFU broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a +2.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where INFU advanced for three days, in 173 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 93 of 143 cases where INFU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. INFU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 56 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.661) is normal, around the industry mean (4.204). P/E Ratio (32.952) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.180) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (1.817) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INFU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of external ambulatory infusion pumps
Industry MedicalNursingServices
Advertisement